Vir Biotechnology Inc Net Assets
Vir Biotechnology Inc net assets. Based on the latest financial reports, Vir Biotechnology Inc (VIR) has net assets worth $982.49 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.21 Billion) and total liabilities ($232.31 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Vir Biotechnology Inc (VIR) equity growth momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $982.49 Million |
| % of Total Assets | 80.88% |
| Annual Growth Rate | N/A |
| 5-Year Change | -46.55% |
| 10-Year Change | N/A |
| Growth Volatility | 52.29 |
Net Assets of Vir Biotechnology Inc (2017–2025)
Net assets of Vir Biotechnology Inc from 2017 to 2025. This chart illustrates how Vir Biotechnology Inc's net assets have evolved over time, based on quarterly financial data. See Vir Biotechnology Inc balance sheet independence to measure how much of total assets are equity-financed.
Annual Net Assets for Vir Biotechnology Inc (2017–2025)
The table below shows the annual net assets of Vir Biotechnology Inc from 2017 to 2025. For live market cap and overall valuation, see VIR market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $765.28 Million | -33.48% |
| 2024-12-31 | $1.15 Billion | -27.66% |
| 2023-12-31 | $1.59 Billion | -23.47% |
| 2022-12-31 | $2.08 Billion | +45.12% |
| 2021-12-31 | $1.43 Billion | +99.74% |
| 2020-12-31 | $716.85 Million | +69.09% |
| 2019-12-31 | $423.94 Million | +336.61% |
| 2018-12-31 | $-179.18 Million | -159.99% |
| 2017-12-31 | $-68.92 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vir Biotechnology Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 111981900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Vir Biotechnology Inc Net Assets Breakdown (December 2025)
Vir Biotechnology Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $14.00K | 0.00% |
| Other Comprehensive Income | $-2.06 Million | -0.27% |
| Other Components | $1.97 Billion | 256.78% |
| Total Equity | $765.28 Million | 100.00% |
Vir Biotechnology Inc Competitors by Market Cap
The table below lists competitors of Vir Biotechnology Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Xinhua Winshare Publishing and Media Co Ltd
SHG:601811
|
$1.88 Billion |
|
XiaMen HongXin Electron-tech Co Ltd
SHE:300657
|
$1.88 Billion |
|
China Enterprise Co Ltd
SHG:600675
|
$1.88 Billion |
|
Federal Agricultural Mortgage Corporation
NYSE:AGM
|
$1.88 Billion |
|
EMBOTELL. ANDINA ADR A/6
F:AKOA
|
$1.88 Billion |
|
Ziff Davis Inc
NASDAQ:ZD
|
$1.88 Billion |
|
Primarius Technologies Co. Ltd. A
SHG:688206
|
$1.88 Billion |
|
Region Group
AU:RGN
|
$1.88 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vir Biotechnology Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,150,385,000 to 765,276,000, a change of -385,109,000 (-33.5%).
- Net loss of 437,987,000 reduced equity.
- Other comprehensive income decreased equity by 340,000.
- Other factors increased equity by 53,218,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-437.99 Million | -57.23% |
| Other Comprehensive Income | $-340.00K | -0.04% |
| Other Changes | $53.22 Million | +6.95% |
| Total Change | $- | -33.48% |
Book Value vs Market Value Analysis
This analysis compares Vir Biotechnology Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.05x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-9.88 | $11.30 | x |
| 2018-12-31 | $-1.85 | $11.30 | x |
| 2019-12-31 | $3.94 | $11.30 | x |
| 2020-12-31 | $6.02 | $11.30 | x |
| 2021-12-31 | $10.73 | $11.30 | x |
| 2022-12-31 | $15.41 | $11.30 | x |
| 2023-12-31 | $11.86 | $11.30 | x |
| 2024-12-31 | $8.44 | $11.30 | x |
| 2025-12-31 | $5.52 | $11.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vir Biotechnology Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -57.23%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -638.87%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 1.31x
- Recent ROE (-57.23%) is below the historical average (-18.05%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | -46880.54% | 0.00x | 0.00x | $-62.96 Million |
| 2018 | 0.00% | -13350.69% | 0.00x | 0.00x | $-97.97 Million |
| 2019 | -41.20% | -24568.64% | 0.00x | 1.21x | $-217.08 Million |
| 2020 | -41.66% | -391.09% | 0.08x | 1.28x | $-370.35 Million |
| 2021 | 36.92% | 48.25% | 0.56x | 1.36x | $385.40 Million |
| 2022 | 24.82% | 31.92% | 0.58x | 1.35x | $308.04 Million |
| 2023 | -38.68% | -713.69% | 0.04x | 1.21x | $-774.08 Million |
| 2024 | -45.37% | -703.40% | 0.05x | 1.22x | $-637.00 Million |
| 2025 | -57.23% | -638.87% | 0.07x | 1.31x | $-514.51 Million |
Industry Comparison
This section compares Vir Biotechnology Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $126,960,080
- Average return on equity (ROE) among peers: -97.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vir Biotechnology Inc (VIR) | $982.49 Million | 0.00% | 0.24x | $1.88 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $29.61 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $4.06 Million | -282.32% | 0.21x | $248.75 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $15.18 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $59.19 Million | -23.76% | 0.21x | $834.03 Million |
| ABVC Biopharma Inc (ABVC) | $13.30 Million | -59.47% | 0.58x | $26.65 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $7.56 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $17.86 Million | -80.65% | 0.23x | $3.55 Billion |
About Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those ta… Read more